Myeloproliferative Disorders Drugs Market Report 2026

The myeloproliferative disorders drugs market size has grown steadily in recent years. It will grow from $9.83 billion in 2025 to $10.17 billion in 2026 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to high prevalence of myeloproliferative disorders, advancements in chemotherapy, growing awareness of blood cancers, availability of generic drugs, supportive care improvements.

The myeloproliferative disorders drugs market size is expected to see steady growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to emergence of targeted therapies, increasing r&d investments, adoption of precision medicine, expansion of healthcare infrastructure in emerging markets, favorable regulatory approvals. Major trends in the forecast period include personalized treatment development, increased focus on rare blood disorders, advancements in targeted therapies, expansion of clinical trials, rising investment in orphan drugs.

The increasing incidence of myeloproliferative disorders is expected to drive the growth of the myeloproliferative disorders drugs market in the coming years. Myeloproliferative disorders are a varied group of diseases that are distinct from acute leukemia and are characterized by the excessive production of one or more hematologic cell lines in the peripheral blood. The rise in these disorders is largely attributed to factors such as genetic abnormalities, prolonged exposure to radiation, electrical wiring or chemicals, and the growing geriatric population. Drugs used to treat myeloproliferative disorders work by inhibiting the BCR-ABL protein through binding to the ATP pocket at the active site, thereby preventing downstream phosphorylation of the target protein and aiding in disease management. For instance, in June 2025, according to the American Cancer Society, a US-based non-profit organization, there are approximately 9,560 new cases and 1,290 deaths from chronic myeloid leukemia each year. This condition accounts for about 15% of all newly diagnosed leukemia cases in the United States, affects nearly 1 in 500 individuals over their lifetime, and is most commonly diagnosed around the age of 66, although around 2% of cases occur in individuals under 20 years of age. Therefore, the rising prevalence of myeloproliferative disorders is contributing to the growth of the myeloproliferative disorders drugs market.

Key players operating in the myeloproliferative disorders drugs market are concentrating on the development and regulatory approval of advanced drug therapies to strengthen their competitive position. The launch and authorization of innovative treatment options are expected to significantly enhance access to advanced therapies for patients with myeloproliferative disorders. For example, in September 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced that the National Institute for Health and Care Excellence approved Jakavi (ruxolitinib), a JAK 1/2 inhibitor indicated for the treatment of polycythaemia vera. This approval enables patients in England and Wales to access ruxolitinib, addressing an unmet treatment need, as nearly 24% of patients receiving hydroxycarbamide or hydroxyurea develop resistance or intolerance. Polycythaemia vera, a subtype of myeloproliferative disorder, is a rare and life-threatening blood cancer associated with excessive red blood cell production, which can lead to serious complications such as heart attack or stroke if left untreated. In the United Kingdom, an estimated 1,130 new cases of polycythaemia vera are diagnosed each year.

In November 2025, Galecto, Inc., a US-based clinical-stage biopharmaceutical company, acquired Damora Therapeutics for an undisclosed sum. Through this acquisition, Galecto intends to enhance and broaden its myeloproliferative neoplasms pipeline by incorporating Damora’s anti-mutant calreticulin antibody programs, thereby accelerating the development of next-generation targeted therapies. Damora Therapeutics is a US-based biotechnology company dedicated to developing antibody-based treatments targeting mutant calreticulin-driven myeloproliferative neoplasms.

Major companies operating in the myeloproliferative disorders drugs market are Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Hikma Pharmaceuticals plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., Astellas Pharma Inc., Daiichi Sankyo Chemical Pharma Co. Ltd.

North America was the largest region in the myeloproliferative disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myeloproliferative disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the myeloproliferative disorders drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized manufacturing equipment, causing delays in production and supply chain disruptions. Segments like JAK2 inhibitors and anti-neoplastics are most affected, particularly in regions such as North America and Europe, which rely heavily on imports for advanced therapies. Some positive impacts include incentivizing local manufacturing and promoting domestic production of high-value drugs, potentially improving supply resilience.

The myeloproliferative disorders drugs market research report is one of a series of new reports that provides myeloproliferative disorders drugs market statistics, including myeloproliferative disorders drugs industry global market size, regional shares, competitors with a myeloproliferative disorders drugs market share, detailed myeloproliferative disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myeloproliferative disorders drugs industry. This myeloproliferative disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myeloproliferative disorder drugs are medications used for the treatment of blood cancers caused by abnormalities in stem cells within the bone marrow, the tissue responsible for producing blood cells. These drugs are used to manage various types of blood malignancies, including myelodysplastic and myeloproliferative disorders.

The main types of myeloproliferative disorder drugs include primary myelofibrosis, polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia or hypereosinophilic syndrome (HES), and systemic mastocytosis (SM). Primary myelofibrosis is a rare, chronic blood disorder characterized by abnormal fibrous tissue formation in the bone marrow, which leads to reduced blood cell production and scarring. The major drug classes used include JAK2 inhibitors, antineoplastic agents, demethylating agents, imatinib mesylate, and others. These medications are administered through oral, parenteral, and other routes and are distributed through hospital pharmacies, retail stores, and drug stores.

The myeloproliferative disorder drugs market consists of sales of jasatinib, nilotinib, jakafi, hydroxyurea, and gleevec. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.